Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Fujifilm Commences Japan PI Study of Radioisotope Conjugate Antibody FF-21101
April 27, 2020
- Chugai’s Q1 Earnings Brisk on Hemlibra, Oncology Franchise
April 24, 2020
- Life Science Institute’s Muse Cell Product Shows Safety, Tolerability in 2 Trials
April 24, 2020
- Biogen Delays US Aducanumab Filing to Q3, but Keeps Japan’s 2020 Plan Intact
April 24, 2020
- CMIC Group to Support Clinical Trial, Manufacturing of Avigan for COVID-19 Treatment
April 24, 2020
- Kyorin’s Coronavirus Detection Reagent Now Available
April 24, 2020
- Relugolix Combo Improves Endometriosis, Non-Menstrual Pelvic Pain in PIII: Myovant
April 24, 2020
- Gene Techno CEO Eyes Lucentis Biosimilar Launch in November 2021, Expects Share of “At Least 30%”
April 23, 2020
- World’s 1st Topical JAK Inhibitor to Hit Shelves on June 24: JT/Torii
April 23, 2020
- Nichi-Iko Recall Hits Towa’s Teprenone Supply
April 23, 2020
- Pfizer Japan Further Extends Work-from-Home through May-End
April 23, 2020
- Remicade Biosimilars OK’ed for Behcet’s-Associated Uveitis
April 23, 2020
- Ube Industries to Start Avigan Intermediate Supplies from July
April 23, 2020
- Myovant Files Relugolix for Advanced Prostate Cancer in US
April 23, 2020
- JCR to Develop 2 Mucopolysaccharidosis Drugs Using BBB-Penetrating Technology
April 23, 2020
- Japan Heading into Earnings Season amid Coronavirus Woes
April 22, 2020
- Shin Nippon Biomedical Joins AnGes Vaccine Development
April 22, 2020
- Drug Makers Restricting Nafamostat Supplies as Hopes Grow for Its Repurposing for COVID-19
April 22, 2020
- Ehime Univ., Sumitomo Dainippon Decipher Mechanism of Action of Malaria Vaccine Candidate
April 22, 2020
- Positive Data in Hand, Ono/Takeda to Seek 1st-Line RCC Nod for Opdivo/Cabometyx Combo
April 22, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…